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Abstract
Background: Little information is available from community-based long-term VTE cohort studies
to compare the absolute thrombosis risk of established clinical and genetic risk factors.
Materials and methods: The occurrence of venous thromboembolism (VTE) was observed
during a 10-year observation period in the BAvarian ThromboEmbolic Risk (BATER) study, a
cohort study of 4337 women (age 18–55 years). We collected data on demographics, reproductive
life, lifestyle, conditions/diseases, and particularly potential risk factors for VTE with a self-
administered questionnaire. The objective was to present incidence rates of VTE and to show
relative risk estimated associated with different clinical and genetic risk factors.
Results: 34 new, by diagnostic means confirmed VTE events occurred during the observation time
of 32,656 women-years (WY). The overall incidence of VTE was 10.4 per 104 WY. The incidence
rates varied markedly among different risk cohorts. The highest incidence was observed in women
with previous history of VTE, followed by family history of VTE. None of the measured "genetically-
related risk markers" (antithrombin, protein C, FVL, prothrombin mutation, or MTHFR) showed a
significant VTE risk.
Conclusion: Most of the discussed VTE risk factors showed no significant association with the
occurrence of new VTEs due to smallness of numbers. Only first-degree family history of VTE and
own history of a previous VTE event depicted a significant association with future VTE. Clinical
information seems to be more important to determine future VTE risk than genetically related
laboratory tests.
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Background
Long-term, community-based cohort studies designed to
evaluate or compare both the risk of inherited and
acquired risk factors for venous thromboembolism (VTE)
in young women are lacking, only one Danish cohort
study designed and conducted to examine cardiovascular
risk factors and the relation with factor V Leiden (DNA
was obtained later during follow-up) [1].
Information is rare on comparative differences in inci-
dence rates and risk estimates across different clinical and
inherited VTE risk factors generated in a community, i.e.
making head-to-head comparisons possible within one
study.
A community-based thromboembolic risk factor study
started in the mid-1990s in Bavaria, the BAvarian Throm-
boEmbolic Risk study (BATER), focused on women in the
reproductive age [2-4]. Clinical and hereditary risk mark-
ers for VTE, the lifetime history of relevant conditions or
medications, and the family history of cardiovascular dis-
eases were documented from 1993 throughout the fol-
low-up period until 2003, i.e., carefully reviewing
complaints or findings possibly related to the occurrence
of venous clots.
The aim of this paper is to present risk estimates for VTE
risk markers available in one study, and to provide inci-
dence rates associated with these risk factors based on new
VTE cases observed during follow-up.
Methods
Material and methods of this long-term cohort study has
been described in detail in earlier publications [2,3] and
particularly in a recent publication in this journal [4]. In
brief, we examined a cohort of 4337 young women (18–
55 years) living in Bavaria who had at least one follow-up.
Data on demography, reproductive life, conditions/dis-
eases, and particularly potential risk factors for VTE were
collected through a self-administered questionnaire and
subsequent telephone enquiries – if necessary- to supple-
ment, clarify and verify the information in the question-
naires to set up the year 1993 as common starting point
for all cohort members.
The source for the data on new (incident) VTE cases was
the follow-up questionnaire (self-reported VTE or symp-
toms potentially compatible with VTE) completed by the
study participants. This information was complemented
by telephone interviews with the woman and with the
treating physician. An external medical reviewer assigned
all suspected VTE cases to one of five categories following
an a priori defined decision scheme: DEFINITE (confir-
mation by imaging test), PROBABLE (unequivocal imag-
ing test, other confirmatory tests positive, and
anticoagulant therapy), POSSIBLE (unequivocal imaging
test, suspicion in other tests, but no anticoagulant ther-
apy), POTENTIAL (only clinical diagnosis without addi-
tional diagnostics, and no anticoagulant therapy), and
NO VTE (alternative diagnosis). Details were given in a
recent publication in this journal [4].
Possible and potential VTE cases were excluded from the
analyses in this paper because of diagnostic uncertainty.
Women with a history of cancer, with chronic liver dis-
eases, or with known antiphospolipid syndrome were not
present in the study.
After having given informed consent the women included
in this study gave a blood sample at entry into the study.
An independent ethics committee approved all study
related activities.
Whole blood samples were obtained from resting sub-
jects. Blood was put into tubes with trisodium citrate.
Plasma was prepared soon after venipuncture by centrifu-
gation for 15 minutes with 3000 to 4000 rpm at room
temperature and stored at - 20°C.
Protein C and antithrombin activities in plasma were
measured by chromogenic substrate assays (Dade
Behring, Marburg, Germany). For antithrombin (AT) the
activity against factor IIa was determined, Protein C activ-
ity was measured after activation of the proenzyme by
snake venom. Plasma activities are given as percentage (%
of normal) of pooled human normal plasma.
Protein C deficiency was defined as less than 77% of nor-
mal (5th percentile of the non-cases of the cohort). Anti-
thrombin deficiency was assumed if less than 81% of
normal (5th percentile)
Genomic DNA was isolated by mean of QIAmp® DNA
Blood Kit (Qiagen) according to the manufacturer's
instructions. The genetic polymorphisms Factor V R506Q
(G1691A), Prothrombin G2010A and 5-, 10-methylene-
tetrahydrofolate reductase (MTHFR) A223V (C677T) were
determined using a multiplex PCR with allele-specific
primers slightly modifying a previously described method
[5].
All blood tests were performed in a blinded manner, i.e.
the investigators had no clinical information, nor access
to the clinical database.
The database was structured to accommodate both con-
current as well as time-dependent variables. Concurrent
variables are variables, which describe the woman's statusThrombosis Journal 2005, 3:8 http://www.thrombosisjournal.com/content/3/1/8
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at the time of questionnaire response, whereas the out-
come variable is time-dependent. While concurrent varia-
bles were held in a fixed dataset, a periodic dataset
containing information on the occurrence of VTE events
along a time axis was created for each participant, using
months as a unit of measurement. In this dataset, all expo-
sures of interest in this paper, such as VTE risk factors
including genetic markers, refer to the baseline point.
Some of the variables of interest (age, BMI, Protein C, AT)
were continuous. These variables were dichotomized in
order to define a categorical exposure status (exposed –
non-exposed) for the analyses based on incidence or
logistic regression. We arbitrarily separated the contin-
uum in two roughly equal intervals such as age under/
over 30 or BMI under/over 25 (kg/m2) in order to have
sufficient cases for analyses with further stratification. For
protein C and AT we used the lower 5th percentile (of the
distribution in non-cases) as cut off point. This limit was
considered as usual definition for "deficiency" and there-
fore clinically relevant [6].
Simple descriptive tables were prepared. All analyses con-
cerning the occurrence of VTE events over time were per-
formed by adding up individual observation time (1993
until the last contact) for different exposure cohorts and
in total.
Apart from the overall VTE incidence rate per 10,000
women-years of observation (WY), we calculated also
incidence rate ratios to compare the incidence of different
sub-groups, e.g., women with factor V Leiden (FVL) muta-
tion compared with women without this genetic
mutation.
The calculation of the relative risk of occurrence of VTE is
based on logistic regression analysis. Crude and adjusted
odds ratios (OR) are reported with 95 % confidence inter-
vals (95% CI).
All analyses were performed with the statistical packages
SAS 8.2 or STATA 8.2.
Results
The overall cohort encompasses 4337 women with suffi-
cient information in 1993 and one follow-up at mini-
mum. The observational period for our current analysis
was 32,656 WYs since 1993.
Initially, 6082 eligible women were invited to join the
study. Of these, 4372 (71.9%) agreed to participate in the
follow-up and with the blood sampling. The main reason
for non-participation was blood sampling.
Table 1: Distribution of clinically and genetically relevant 
variables in a cohort of women at baseline of the observational 
period 1993 – 2003. The total number of women in this analysis 
is 4320, i.e. excluding 17 women with a final diagnosis of a 
possible/potential VTE. Deviations from this number are due to 
missing information
Variables
Continuous variables n Mean 
(SD)
Age (years) 4320 26.0 
(8.6)
Life births, number 1910 1.7 (0.8)
BMI§ 4309 23.3 
(4.1)
Protein C (% of normal) 4315 102.4 
(15.8)
AT (% of normal) 4316 98.4 
(11.3)
Categorical parameters Percent 
(%)
Own history of VTE No 4279 99.0
Yes 41 1.0
Family history No 3840 88.9
Yes 480 11.1
Age, alternative <30 2843 65.8
≥  30 1477 34.2
Family history of varicous veins No 2395 55.4
Yes 1925 44.6
Family history of MI No 3830 88.7
Yes 490 11.3
BMI, alternative <25 3218 74.7
≥  25 1091 25.3
Ever use of hormone replacement No 4031 93.7
Yes 270 6.3
Family history of stroke No 4013 92.9
Yes 307 7.1
Ever use of oral contraceptives No 346 8.0
Yes 3973 92.0
Education level: Abitur& No 3119 73.2
Yes 1139 26.8
Ever smoker No 2022 46.8
Yes 2296 53.2
Laboratory & genetic markers
Factor V Leiden mutation1 No 4035 93.7
Yes 271 6.3
Prothrombin mutation1 No 4088 96.6
Yes 142 3.4
MTHFR1 No 1798 42.5
Yes 2432 57.5
Protein C deficiency# No 4117 95.4
Yes 198 4.6
AT deficiency# No 4106 95.1
Yes 210 4.9
1 Homozygote & heterozygote together
§
Body mass index (kg/m2)
&maturity for university
# definition see methodsThrombosis Journal 2005, 3:8 http://www.thrombosisjournal.com/content/3/1/8
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The follow-up was carried out until 2003 at most, or oth-
erwise terminated at the time when the last contact was
possible to get information about new conditions that
may have had occurred. 2076 women could be followed
up until 2002/3 (47.9 %), 595 (13.7%) women did not
participate in follow-ups before 1999–2001, and the larg-
est proportion of women dropped out during the first
years before 1999 (38.4%). Thus, the follow-up period
was censored some time before 2002/3 for approximately
half of the cohort members, i.e. the last successful contact
was defined as "end of follow-up".
Thirty-four new cases of VTE occurred in the observational
period. These cases were finally confirmed and catego-
rized according to diagnostic certainty by an independent
medical reviewer as definite (n = 31) or probable (n = 3).
Cases with possible/potential VTE (n = 17) were excluded
from further analyses because of low diagnostic certainty,
i.e. it was not clear whether to classify them in the group
cases or non-cases.
Out of the 34 definite/probable VTE cases 18 cases (=
52.9%) were associated with "clinical causes for VTE" and
16 (= 47.1%) were so-called "idiopathic" VTEs. The fol-
lowing "clinical causes" were observed prior to occurrence
of the new VTE: 4 with previous VTE, 3 pregnancy/puer-
perium, 4 after an accident, 2 after surgery, 3 immobiliza-
tion, and 2 after long travel in sitting position.
Table 1 depicts the profile of relevant data available at
baseline (1993) to get an impression of the group under
follow-up.
The mean age was 26 ± 8.6 years, however, for the dichot-
omized age variable we used as cut-off point 30 years
resulting in strata that contained VTE cases in both age
groups. The frequency of other data, family history (first
degree relatives) of potentially relevant diseases, condi-
tions and genetic lab parameters is provided in the table
1. Homo-and heterozygote carriers of mutation were ana-
lyzed together because of small numbers or homozygote
carriers.
Table 2 presents the characteristics of the 34 VTE cases and
the remaining "non-cases" in the cohort. Varying total
numbers in the table are due to missing information par-
ticularly in non-cases and genetic characteristics.
There were some remarkable differences between cases
and non-cases that affected differences in VTE risk esti-
mates in further analyses such as incidence rates, inci-
dence rate ratios as well as relative risk estimates (see
Table 2: Description of the subgroup of VTE cases and non-cases regarding parameters considered in this study as potential VTE risk 
factors at baseline of the observation period 1993 – 2003 Only definite and probable VTEs were considered as cases in this table, i.e. 
possible & potential VTE were excluded. Definitions of variables see text.
Non-cases VTE cases Total cohort
N n (%) N n (%) N n (%)
Demographic data
Age*: 30+ years 4286 1456 (34.0) 34 21 (61.8) 4320 1477 (34.2)
BMI*: 25+ 4275 1076 (25.2) 34 15 (44.1) 4309 1091 (25.3)
OC use: yes, ever 4285 3941 (92.0) 34 32 (94.1) 4319 3973 (92.0)
Other hormones: yes, ever 4267 267 (6.3) 34 3 (8.8) 4301 270 (6.3)
Smoking: yes, ever 4284 2278 (53.2) 34 18 (52.9) 4318 2296 (53.2)
Medical history
Personal history of VTE*: yes 4286 37 (0.9) 34 4 (11.8) 4320 41 (1.0)
Family history of VTE*: yes 4286 470 (11.0) 34 10 (29.4) 4320 480 (11.1)
Family history of varicose veins*: yes 4286 1902 (44.4) 34 23 (67.7) 4320 1925 (44.6)
Family history of MI*: yes 4286 482 (11.3) 34 8 (23.5) 4320 490 (11.3)
Family history of stroke: yes 4286 302 (7.1) 34 5 (14.7) 4320 307 (7.1)
Laboratory & genetic markers
FVL mutation§: yes 4273 267 (6.3) 33 4 (12.1) 4306 271 (6.3)
Prothrombin mutation§: yes 4199 140 (3.3) 31 2 (6.5) 4230 142 (3.4)
Protein C deficiency #: yes 4281 4087 (95.5) 34 30 (88.2) 4315 4117 (95.4)
AT deficiency #: yes 4282 4073 (95.1) 34 33 (97.1) 4316 4106 (95.1)
MTHFR§: yes 4199 2415 (57.5) 31 17 (54.8) 4230 2432 (57.5)
§ homo- and heterozygote together
* significant difference between VTE cases and non-cases (p < 0.05)
# definition see methodsThrombosis Journal 2005, 3:8 http://www.thrombosisjournal.com/content/3/1/8
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below): cases were found to be older, to have a higher pro-
portion of elevated BMI, of history of previous VTE, of
family history of VTE (first degree relatives). Family
history of varicose veins, myocardial infarction, and
stroke were included not as VTE risk factors, but condi-
tions with a potential for misclassification by respondents
(past history was not validated).
Although the frequency of known genetic risk factors for
VTE (specifically FVL mutation and prothrombin muta-
tion) seemed to be higher in cases than non-cases, this
was not statistically significant (see comparisons below).
Only 6 of the 34 women suffering from definite or proba-
ble VTE showed any established marker of thrombophilia
in the laboratory screen. Two of 6 patients in this group
had severe thrombophilia with the combination of Pro-
tein C deficiency (48 % activity) and heterozygous Factor
V Leiden or a homozygous FVL mutation. The other 3
patients exhibited only one positive laboratory marker
and were either heterozygous for FVL (n = 2) or pro-
thrombin mutation (PTM, n = 1). The numbers however
were too small for sub-analyses. 24 patients showed no
detectable marker of thrombophilia, 2 out of these
patients demonstrated a homozygous MTHFR mutation.
We observed 34 new definite/probable VTE cases within
the 32,508 WYs of observation, i.e., an incidence rate of
10.4 per 10,000 WYs.
Table 3 shows incidence rates of VTE stratified by presence
(= exposed) or absence (= non-exposed) of the variables
considered as potential "risk factors" in this analysis.
Marked differences of incidence rates were observed
across the variables listed in table 3, i.e., comparing the
incidence between exposed and non-exposed in each of
the variables. Several of the 15 compared parameters
showed significantly elevated incidence rate ratios (rela-
tive risk): some demographic variables (advanced age, ele-
vated BMI), data of the medical history (history of
previous VTE, family history of VTE or family history of
Table 3: Incidence rates for VTE (definite and probable) based on 4320 women and 32,508 WY of observation (1993 – 2003). 
Tabulation by parameters considered as potential VTE risk factors. Descriptive tabulation of events per 10,000 WY in the exposed and 
non-exposed group. Incidence rate ratio (IR) and 95% confidence interval (95% CI). "Exposed" was defined as the group where the risk 
was assumed to be higher.
Exposed Non-exposed Overall Exp. vs. Non-
exposed
Exposed vs. non-exposed WY VTE 
incidence 
per 104 WY
WY VTE 
incidence 
per 104 WY
WY VTE 
incidence 
per 104 WY
IR (95% CI)
Demographic data
Age: 30+ years vs. <30 12,346 17.0 20,162 6.5 32,508 10.5 2.6 (1.3–5.7)
BMI: 25+ vs. <25 8,764 17.1 23,696 8.0 32,460 10.5 2.1 (1.01–4.4)
OC use: ever vs never 30,388 10.5 2,116 9.5 32,504 10.5 1.1 (0.3–9.6)
Other hormones: ever vs. never 2,484 12.1 29,896 10.4 32,380 10.5 1.2 (0.2–3.7)
Smoking: yes, ever 16,878 10.7 15,615 10.2 32,493 10.5 1.04 (0.5–2.2)
Medical history
Personal history of VTE: yes 318 125.8 32,190 9.3 32,508 10.5 13.5 (3.5–38.3)
Family history of VTE: yes 3,810 26.3 28,698 8.4 32,508 10,5 3.1 (1.3–6.8)
Family history of varicous veins: yes 14,764 15.6 17,744 6,2 32,508 10.5 2.5 (1.2–5.7)
Family history of MI: yes 3,919 20.4 28,589 9,1 32,508 10.5 2.2 (0.9–5.1)
Family history of stroke: yes 2,480 20.2 30,028 9,6 32,508 10.5 2.1 (0.6–5.5)
Laboratory & genetic markers
FVL mutation§: yes 2,105 19.0 30,308 9.6 32,413 10.2 2.0 (0.5–5.7)
Prothrombin mutation§: yes 1,010 19.8 30,817 9.4 31,827 9.7 2.1 (0.24–8.3)
Protein C deficiency#: yes 1510 26.5 30,958 9.7 32,468 10.5 2.7 (0.7–7.8)
AT deficiency#: yes 1648 6.1 30,828 10.7 32,476 10.5 0.6 (0.01–3.4)
MTHFR§: yes 18,423 9.2 13,404 10.4 31,827 9.7 0.9 (0.4–1.9)
§ homo- and heterozygote together
# definition see methodsThrombosis Journal 2005, 3:8 http://www.thrombosisjournal.com/content/3/1/8
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varicose veins). But to our surprise none of the established
genetic VTE risk markers showed a significantly increased
VTE risk in this analysis. However, taking the risk esti-
mates at face-value, three of the five markers (positive
FVL, prothrombin mutation, and protein C) depicted a 2-
fold increase in risk, although statistically not significant.
These however were only crude comparisons, i.e. do not
account for the simultaneous influence of any of the other
VTE risk factors.
Similar to the evaluation of the relative risk estimates
using the incidence rate ratio in the cohort approach, the
evaluation with crude odds ratios showed an almost iden-
tical set of significant risk markers (table 4): higher age,
elevated BMI, personal history of previous VTE, family
history of VTE & varicose veins, but in addition also family
history of myocardial infarction. None of the five genetic
markers was significantly associated with the VTE risk in
the crude risk assessment.
When the risk assessment of all mentioned parameters
underwent a fully adjusted analysis, i.e. controlling for all
other respective variables, the overall findings approxi-
mately were the same, but only higher age, personal and
family history of VTE increased significantly the risk of
VTE within the 10-year period. None of the genetic mark-
ers had a statistically significant impact on VTE risk – even
not after adjustment for other potential risk factors. How-
ever, the two measured mutations and protein C
remained at an apparently elevated VTE risk level –
although these results were not statistically significant.
Virtually identical risk estimates were observed when the
Cox regression was used instead of the logistic regression
(data not shown), although based again on small num-
bers of exposed cases. Instable risk estimates due to small
numbers and many adjustment variables cannot be
excluded.
No significant interaction terms were found in the analy-
ses (data not shown).
Discussion
To our knowledge, there are no long-term community-
based cohort studies designed to evaluate or compare the
risk of inherited or acquired risk factors for venous throm-
boembolism (VTE) in women under the age of 50 years,
except for a Danish cohort study which, at least initially,
Table 4: Potential VTE risk factors and risk estimates for VTE (definite and probable) based on 4320 women. Comparative assessment 
with logistic regression analysis: Odds ratio (OR) and 95% confidence interval (95% CI)
Non-cases Cases Crude OR
(95% CI)
Adjusted* OR 
(95% CI)
Non-exposed Exposed Non-exposed Exposed
Demographic data
Age: 30+ years vs. <30 2830 1456 13 21 3.1 (1.6–6.3) 2.4 (1.1–5.3)
BMI: 25+ vs. <25 3199 1076 19 15 2.3 (1.2–4.6) 2.0 (0.9–4.1)
OC use: ever vs never 344 3941 2 32 1.4 (0.3–5.9) 1.3 (0.3–5.8)
Other hormones: ever vs. never 4000 267 31 3 1.4 (0.4–4.8) 0.86 (0.2–2.9)
Smoking: ever vs. never 2006 2278 16 18 1.0 (0.5–1.9) 0.8 (0.4–1.7)
Medical history
Personal history of VTE: yes vs. no 4249 37 30 4 15.3 (5.1–45.9) 6.6 (1.8–24.6)
Family history of VTE: yes vs. no 3816 470 24 10 3.4 (1.6–7.1) 2.4 (1.0–5.4)
Family history of varicous veins: yes vs. no 2384 1902 11 23 2.6 (1.3–5.4) 1.9 (0.8–4.1)
Family history of MI: yes vs. no 3804 482 26 8 2.4 (1.1–5.4) 2.0 (0.8–4.6)
Family history of stroke: yes vs. no 3984 302 29 5 2.3 (0.9–5.9) 1.2 (0.4–3.5)
Laboratory & genetic markers
FVL mutation§: yes 4006 267 29 4 2.1 (0.7–5.9) 2.0 (0.7–6.0)
Prothrombin mutation§: yes 4059 140 29 2 2.0 (0.5–8.5) 2.3 (0.5–10.0)
Protein C deficiency#: yes 4087 194 30 4 2.8 (0.98–8.0) 3.0 (0.9–10.4)
AT deficiency#:yes 4073 209 33 1 0.6 (0.1–4.3) 0.5 (0.1–3.5)
MTHFR§: yes 1784 2415 14 17 0.9 (0.4–1.8) 0.95 (0.5–1.97)
§ homo- and heterozygote together
# definition see methods
* adjusted for all other variablesThrombosis Journal 2005, 3:8 http://www.thrombosisjournal.com/content/3/1/8
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targeted general at cardiovascular risk factors and not VTE
specifically (DNA was obtained later during follow-up)
[1]. Moreover, this study was specifically focused on factor
V Leiden.
It was our aim to evaluate or compare the absolute risk
and risk ratio of established clinical or genetic risk mark-
ers for VTE. In the past, most risk factor studies for VTE
were restricted to clinically available markers such as age,
BMI, previous VTE, family history, or acute factors (immo-
bilization, surgery, accidents, pregnancy/puerperium, and
hormonal contraceptive use) and based on clinical or
cross-sectional, observational studies or analyses in
administrative databases. Many observational studies or
cohort studies in young women did not consider inher-
ited factors (overview about incidence and risk factor
studies in [7,8]). Cohort studies in the population rarely
included or reported genetic markers for thrombophilia
and acquired, lifestyle-related risk factors, except the Phy-
sicians Health Study for example – the latter however only
for males over 40 years of age [9], or the above mentioned
Danish cohort study [1].
Other studies with focus on markers for hereditary throm-
bophilia were performed in patients (e.g. in anticoagulant
clinics), in relatives of carriers of genetic mutations but
not in the general population [6,10-12]. Point estimates
for thrombosis-free survival in carriers of major throm-
bophilic states are often restricted to the selected cohort of
family members only (overview in Crowther [13]). More-
over, the evaluation of genetic markers often does not
consider the impact of clinically available risk factors and
the design was mainly restricted to clinical or case-control
studies.
Thirty-four VTE cases, classified as definite or probable,
occurred within this period, which is equivalent with
about 10 per 10,000 WYs. At the first glance, this inci-
dence seems to be high. However, this might be the result
of the specifics of our study: We put great effort on the
detection of potential cases and – even more important –
we included all definite and probable cases, whereas most
of the reported incidence rates in young women refer only
to "confirmed" and so-called "idiopathic VTE", i.e.
excluded all cases that occurred in temporal relationship
to other potential reasons such as pregnancy/puerperium,
surgery, or immobilization, for example. A similar overall
incidence rate of 12.3 events/104  person-years was
observed in the Danish cohort study [calculated from – 1
-], which however covers both gender and a higher mean
age (45 years in the Danish study vs. 26 years in our
study).
Idiopathic VTE, however, reflects only a smaller part of all
confirmed VTE cases [14]. In our cohort study we found
roughly 53 % so-called "idiopathic" (primary) VTE cases,
and the other roughly 47% of cases had a previous VTE in
their history, or pregnancy/puerperium, surgery, or other
reasons for immobilization/long bed-rest shortly prior to
the VTE event. Thus, the incidence of "idiopathic VTE"
observed in this study can be estimated to be about 5 per
10,000 WY. This is in agreement with other reported inci-
dence rates in the general population [1,7]. The incidence
estimates for definite VTE ranges between 1 to 6 per 104
WY in non-users or oral contraceptives (OC) and 2 to 10
per 104 WYs in OC users. Older studies depicted almost-
always higher incidence rates than more recently per-
formed studies (see overview in [7]). A recent systematic
review [8] came to a pooled incidence of definite VTE for
the general population of 5 per 10,000 person years, sim-
ilar in males and females, and found that around 40% of
VTE cases were "idiopathic". We conclude that our data
can be generalized for the female population of this
region in the fertile age range. This conclusion is sup-
ported by results of a prospective, community-based
cohort study [9] that found a VTE incidence rate of 2.7
"primary VTE cases" per 104 person-years (equal to idio-
pathic: no previous VTE history, no cancer, no surgery or
trauma), however, in males aged 40–49 years.
The absolute risks (incidence rates) varied markedly
among those exposed or non-exposed by genetic and
acquired VTE risk factors in our cohort study (see table 3).
The relatively small numbers of women exposed to
genetic VTE markers (see also table 2) should be taken
into account before drawing conclusions. Thus, we have
to be worry about statistically robust results in most of the
sub-groups.
The crude, not adjusted comparison between "exposed"
(= risk factor present) and "non-exposed" (= risk factor
absent) showed incidence ratios (OR) ranging from 0.6
(AT deficiency) to 13.5 (personal history of VTE). The
highest VTE incidence rate was found for women with a
history of previous VTE (125.8 VTE cases per 104 WY –
compared with 9.3 in women without VTE history), i.e., a
13.5fold increased incidence rate ratio (see table 3). Other
significant incidence rate ratios were observed for higher
age, elevated BMI, family history of VTE (and for varicose
veins).
After fully controlling for all other risk factors (logistic
regression) only age, personal and family history of VTE
remained significant risk factors (see table 4). A significant
role of the family history of VTE has been reported in sev-
eral studies [15-17]. It is surprising that in our study the
aggregate variable "family history" was more important
than the individual genetic or related markers.Thrombosis Journal 2005, 3:8 http://www.thrombosisjournal.com/content/3/1/8
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The impact of individual genetic markers on VTE risk
(FVL, PTM, MTHFR) was not statistically significant in the
logistic regression analysis (table 4) – possibly also due to
the small number of incident cases. This is also true for
Protein C and AT deficiency, i.e. when using the lower 5th
percentile as usual definition for deficiency [18]. Even FVL
mutation did not show significantly increased VTE risk,
although the point estimate (OR = 2.0) – at face-value – is
compatible with the estimate of another, but much larger
cohort study [1], but lower than reported from several
case-control studies. This difference between risk esti-
mates for FVL in cohort and case-control studies is proba-
bly due to methodological reasons [1].
A similarly weak impact of genetic markers was also
observed in follow-up studies of selected groups: Carriers
of genetic polymorphisms have been followed prospec-
tively and found a low absolute annual incidence of VTE
[10,12,19]. Another prospective cohort observed a low
incidence of VTE in otherwise healthy thrombophilic chil-
dren [20] or asymptomatic family members who are car-
riers of factor V Leiden [11,12] or other family studies
[21]. Deficiency of AT and PC activity had also no signifi-
cant impact on thrombotic risk. We cannot exclude how-
ever that a considerable part of such unexpected results for
PC and AT activity may be related to pre-analytical condi-
tions in our field study. From a laboratory perspective in
a few women polymorphisms leading to decreased levels
of analytical results but not to clinical manifest throm-
bophilia are quite possible. An explanation might be that
silent mutations and polymorphisms cause reduced activ-
ities in the laboratory assays not reflecting a potential clin-
ical problem [22,23]. Without a positive personal or
family history of VTE such results should at least be con-
firmed with additional laboratory tests and family
examinations before informing the patients of a potential
thrombophilic diathesis or before recommending respec-
tive medical prophylaxis.
There is an increasing debate about the role of genetic fac-
tors in the prediction of future VTEs and thus sustaining a
controversy about genetic screening. This issue is a current
controversy in the literature [24,25]. Clinical reports often
suggest a high VTE recurrence rate in patients with previ-
ous VTE [26], but we found this phenomenon only in 4 of
our 34 incident VTE cases. A recently published commu-
nity-based cohort study of FVL carriers & non-carriers
observed no significant difference on VTE incidence
between both groups, except for women ≥  60 years of age
[27].
In general, our results support the notion that genetic
parameters alone are relatively weak long-term risk fac-
tors; the occurrence of VTE requires interaction of both
inherited and acquired risk factors or gene-gene-interac-
tions [28].
The clinical VTE risk factors with significantly elevated
incidence rate ratios such as advanced age and elevated
BMI, but also history of previous VTE, family history of
VTE or family history of varicose veins are not new. Most
physicians are aware of these risk factors and consider
them in practice. No incidence difference was also found
for ever smoking which is rarely considered as risk factor
for VTE. Hypertension was not analyzed. No significant
prognostic impact was found for ever use of hormonal
treatment/contraception at baseline. This is plausible
because sex hormones effects are not general characteris-
tics but short-term acting factors, which need another sta-
tistical approach, and was not the aim of this study.
The influence of more acutely acting risk factors – such as
immobilization, surgery, long-haul flights, and use of
drugs (e.g. OCs) was intentionally excluded from this
analysis, although interactions between hereditary factors
and acute, environmental pattern are known [21,29,30].
Only parameters that were available at baseline and likely
to affect the long-term development were eligible for this
analysis. Other influential risk factors or preventive meas-
ures have to be considered when discussing activities to
reduce a predicted increased risk in the medical practice.
It was not the aim of the study and data are neither avail-
able to test the effect of preventive measures nor the effect
of additional risk factors in the immediate period before
the event occurred. This would require another study
design and a separate study with sufficient power for such
questions.
It is a limitation of this long-term cohort study, however,
that the number of incident, confirmed (definitive and
probable) VTE cases was still small in absolute numbers
(n = 34) in this cohort observation period of 32,508 years
of observation. The low incidence can be explained by the
young average age (26 years at entry). Thus, incidence &
and risk estimates have wide confidence intervals and
conclusions are limited. Rare combinations of risk mark-
ers have not yet materialized in one single VTE case. This
makes it difficult to further divide into cases that occurred
in presumably exposed or unexposed sub-groups. This is
particularly true if the potential risk factors (exposure) are
infrequent, as it is for genetic markers. It is a problem of
the study design that no attempt was made to confirm of
deficiencies (second blood sample) and no family study
was planned to assess inheritance of deficiencies such as
AT or PC.
In case of FVL mutation the adjusted risk is apparently
increased about 2fold (non-significant) but only 4 cases
had a positive test of FVL mutation (for prothrombinThrombosis Journal 2005, 3:8 http://www.thrombosisjournal.com/content/3/1/8
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mutation only 2 cases). If one then adjusts for 14 other
potential factors, there is obviously a statistical problem:
Resulting risk estimates might be unstable, i.e. drifted in
either direction. Even if one focuses on the crude OR,
which is similar to the adjusted estimate in this case, care-
ful interpretation is warranted. It cannot be excluded that
the "true risk" of the mutation markers is 2fold increased,
although the risk estimates do not favor of such a conclu-
sion. Insofar, future analyses will benefit from an
improved point of departure (longer observation, more
cases).
Conclusion
In conclusion, estimation of VTE risk cannot be based on
genetic characteristics alone – but only in combinations
with available clinical information. Genetic markers play
obviously a limited role in the long-term prediction of
VTE. Genetic markers form together with the "environ-
mental circumstances" the disposition, i.e. together with
the family history of cardiovascular events, specifically
venous events. If the disposition translates into an event,
this is obviously more influenced by "longstanding clini-
cal VTE risk factors", factors such as positive medical his-
tory, advanced age, and elevated BMI than specific genetic
factors. However, there are obviously other important,
more acutely affecting environmental factors such as
immobilization, surgery, and treatment with drugs that
influence coagulation. The latter factors can be used to
reduce the basic risk determined by long-term acting
acquired risk factors modulated by inherited factors.
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